Macrophage activation marker sCD163 and sCD206 predict mortality in patients with alcoholic hepatitis
AASLD LiverLearning®, Banishree Saha, 144128
Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype
AASLD LiverLearning®, Asma Ahmed, 144384
Ethanol-Induced Alterations in Pancreatic and Gastric Hormone Secretion Promotes Hepatic Steatosis
AASLD LiverLearning®, Karuna Rasineni, 144129
Longitudinal changes in peripheral CD4+ regulatory T cells upon treatment of chronic hepatitis C with direct-acting antivirals
AASLD LiverLearning®, Bettina Langhans, 144385
Year 2 serum HBV DNA detectability predicts hepatocellular carcinoma in entecavir-treated patients - a 7-year cohort study of 1,680 patients with chronic hepatitis B
AASLD LiverLearning®, Grace Wong, 144142
The Dual Glucagon-Like Peptide-1 (GLP-1)/Glucagon Receptor Agonist MEDI0382 Improves Metabolic and Hepatic Indices of NASH in Mice
AASLD LiverLearning®, James Trevaskis, 144398
Ultra-deep sequencing of circulating tumor DNA identifies druggable mutations: exploring applications of a liquid biopsy in HCC
AASLD LiverLearning®, Ismail Labgaa, 144143
Group 2 Innate Lymphoid Cells (ILC2s) are Altered in Fatty Liver Disease
AASLD LiverLearning®, Lucy Golden-Mason, 144399
Multidisciplinary Tumor Board Adherence to AASLD Treatment Guidelines for Hepatocellular Carcinoma: Does It Matter?
AASLD LiverLearning®, Asrar AlAhmadi, 144144
Necroptosis and its role in steatohepatitis
AASLD LiverLearning®, Jérémie Gautheron, 144400
Immunological characteristics of the tumor-associated antigens in patients with cholangiocarcinoma
AASLD LiverLearning®, Akihiko Kida, 144145
The FXR/TGR5 Dual Agonist INT-767 Reduces NAFLD Activity Score and Fibrosis Stage and Improves Plasma and Hepatic Lipid Profiles in the GUBRA-AMLN Mouse Model of Diet-induced and Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Jonathan Roth, 144401
Non-alcoholic fatty liver disease (NAFLD) is associated with low surveillance rate and advanced hepatocellular carcinoma (HCC) at diagnosis
AASLD LiverLearning®, Yi Huang, 144158
The dual FXR/TGR5 agonist INT-767 inhibits nonalcoholic steatohepatitis development in a rabbit model of metabolic syndrome
AASLD LiverLearning®, Luciano Adorini, 144414
Association of relative liver enhancement of Gd-EOB-DTPA-enhanced magnetic resonance images with histologic grade of hepatocellular carcinoma
AASLD LiverLearning®, Young-Joo Jin, 144159
iPLA2beta deficiency attenuates obesity and steatosis in long-term HFD fed mice through an alteration of hepatic phospholipids
AASLD LiverLearning®, Ann-Christin Otto, 144415
Quantifying the likely benefits and harms of surveillance for hepatocellular carcinoma in patients with cirrhosis
AASLD LiverLearning®, Ian A. Rowe, 144160
Palmitic acid elicits insulin resistance and oxidative cell injury through clusterization of lipid rafts in murine hepatocytes.
AASLD LiverLearning®, Akira Uchiyama, 144416
Sirt6 deletion in liver promotes NASH development by downregulation of Nrf2 in mice fed a high-fat, high-fructose diet.
AASLD LiverLearning®, Sun-O Ka, 144417
Risk factors for liver cancer in chronic hepatitis C are different between the early and late periods after sustained virological response.
AASLD LiverLearning®, RYOKO YAMADA, 144174
L-Selectin (CD62L) drives development and progression of non-alcoholic steatohepatitis (NASH) in two dietary mouse models
AASLD LiverLearning®, Hannah Drescher, 144430
Complete tumor necrosis after loco-regional therapy reduces risk of recurrent HCC after transplant: a UNOS study.
AASLD LiverLearning®, Rex Cheng, 144175
L-carnitine attenuates oxidative stress and inflammatory reactions in steatohepatitis in diabetic KK-Ay mice
AASLD LiverLearning®, Kazuyoshi Kon, 144431
BAP1 modulates expression of long non-coding RNA NEAT1 and contributes to cancer phenotype and sensitivity to gemcitabine in intrahepatic cholangiocarcinoma (iCCA)
AASLD LiverLearning®, Mansi Parasramka, 144176
Trim8 deficiency protects against hepatic steatosis and insulin resistance
AASLD LiverLearning®, peng zhang, 144432
EDP-305, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits high Potency and Efficacy In Vitro and In Vivo
AASLD LiverLearning®, Lijuan Jiang, 144433
Barcelona Clinic Liver Cancer (BCLC) Versus Hong Kong Liver Cancer (HKLC) Staging Systems in an Asian Tertiary Centre - A review of 1270 patients from a multiracial Asian population
AASLD LiverLearning®, Weiquan James Li, 144190
Crystalized cholesterol leads to inflammasome activation and marks the transition from simple steatosis to steatohepatitis in humans with NASH and in mice with high-fat diet-induced steatohepatitis.
AASLD LiverLearning®, Angela Dolganiuc, 144446
Dietary Cholesterol Intake Is Not Associated with Hepatocellular Carcinoma Development or Chronic Liver Disease Related Death in the General Population: The United States Multiethnic Cohort
AASLD LiverLearning®, Lei Yu, 144191
Activating Transcription Factor 3 Is a Targeted Molecule Linking Hepatic Steatosis To Type 2 Diabetes
AASLD LiverLearning®, Won Kim, 144447
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
AASLD LiverLearning®, Masahito Nakano, 144192
Calcium sensing receptor activation increases triglyceride accumulation in HepG2 cells
AASLD LiverLearning®, Pia Villarroel, 144448
The Mixed Lineage Kinase Inhibitor 3 URMC-009 Attenuates Established Murine Nonalcoholic Steatohepatitis
AASLD LiverLearning®, Brittany Freeman, 144449
Safety, Tolerability and Pharmacokinetics of L-Ornithine Phenylacetate in Patients with Acute Liver Injury/Failure
AASLD LiverLearning®, Richard Stravitz, 154954
Treatment-integrated Nomogram of the Barcelona Clinic Liver Cancer System for Patients with Hepatocellular Carcinoma
AASLD LiverLearning®, Chia-Yang Hsu, 144206
EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo
AASLD LiverLearning®, Lijuan Jiang, 144462
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation?
AASLD LiverLearning®, Eun Ju Cho, 144207
Sphingosine 1-Phosphate (S1P)/S1P Receptor 2/3 Mediates M1 Type Polarization of Bone Marrow-Derived Monocytes/Macrophages in Non-alcoholic Steatohepatitis
AASLD LiverLearning®, Liying Li, 144463
Insulin resistance assessment is useful in risk stratification of hepatocellular carcinoma in chronic hepatitis B patients
AASLD LiverLearning®, jung hee kim, 144208
Adiponutrin (rs738409) gene polymorphisms increase the risk and progression of nonalcoholic steatohepatitis (NASH) in Asian Indians
AASLD LiverLearning®, Manvi Vernekar, 144464
Butyrate induces ROS-mediated apoptosis via modulation of miR-22/SIRT-1 pathway in Hepatoma cells.
AASLD LiverLearning®, Kishor Pant, 144465
Quality of Life and Outcomes after Multiple Courses of Granulocyte-Colony Stimulating Factor and Growth Hormone in Patients with Decompensated Cirrhosis
AASLD LiverLearning®, Virendra Singh, 154967
Farnesoid X Receptor Agonist Obeticholic Acid Raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-induced NASH (DIN) Hamster, a Novel Preclinical Model for Evaluating Efficacy and Side effects of Drugs targeting Non-Alcoholic Liver Diseases.
AASLD LiverLearning®, Francois Briand, 154968
Clinical-grade human liver mesenchymal stem cells for the treatment of NASH-Fibrosis through immunomodulation
AASLD LiverLearning®, Kris Gellynck, 154969
YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models
AASLD LiverLearning®, JUN HWAN KIM, 154970
Mortality and morbidity with endoscopic versus percutaneous biliary drainage in palliation of unresectable hilar cholangiocarcinoma: A meta-analysis and systematic review.
AASLD LiverLearning®, Abhiram Duvvuri, 144222
Prognostic significance of sarcopenia in patients with newly diagnosed hepatocellular carcinoma
AASLD LiverLearning®, Yeonjung Ha, 144223
Aroclor 1260 disrupts the hepatic proteome in the development of NASH
AASLD LiverLearning®, Josiah Hardesty, 144479
Short term effect of transarterial chemoembolization (TACE) on microsomal liver function by means of 13C-methacetin breath test (MBT) in patients with hepatocellular carcinoma (HCC)
AASLD LiverLearning®, Oliver Goetze, 144224
Combination of an ASK1 inhibitor and FXR agonist increases anti-fibrotic efficacy in a rat model of NASH
AASLD LiverLearning®, Grant Budas, 144480
Wheat Bran Autolytic Peptide, Containing a Branched-chain Amino Acid, Improves Nonalcoholic Steatohepatitis with Up-regulation of AMPK/ACC/GSK3β Signaling Pathway in High-fat Diet-fed Mice.
AASLD LiverLearning®, Takumi Kawaguchi, 144481
Rosuvastatin prevents the development of hepatocellular carcinoma in mice with nonalcoholic fatty liver disease.
AASLD LiverLearning®, Keisuke Yokohama, 144482
Validation of tumor factor of staging systems in hepatocellular carcinoma; focusing on the difference between each staging system
AASLD LiverLearning®, Sadahisa Ogasawara, 144238
Does Biopsy Aid in the Management of Patients with Hepatocellular Carcinoma Meeting AASLD Diagnostic Imaging Guidelines?
AASLD LiverLearning®, Asrar AlAhmadi, 144239
Metabolomic classification of murine and human nonalcoholic fatty liver disease
AASLD LiverLearning®, Cristina Alonso, 144495
Incomplete RFA causes cell cycle Arrest and enhanced tumor growth - in vitro and in vivo
AASLD LiverLearning®, Th. Till WISSNIOWSKI, 144240
Dietary Iron overload in the context of a ‘nashogenic’ Western diet aggravates nonalcoholic steatohepatitis through increased recruitment and accumulation of hepatic immune mediators.
AASLD LiverLearning®, Priya Handa, 144496
Regulation of Kupffer cell activation by the microRNA-34a/p53 axis during alcoholic liver injury
AASLD LiverLearning®, Tianhao Zhou, 144497
Exosome Derived from Palmitic Acid-treated Hepatocytes Activates Hepatic Stellate Cells
AASLD LiverLearning®, Young-Sun LEE, 144498
Risk of Hepatocellular Carcinoma after Antiviral Therapy in Different Sets of Korean Patients with Chronic Hepatitis C
AASLD LiverLearning®, Sangyoung Yi, 144254
Yttrium-90 (90Y) Radioembolization in the treatment of intrahepatic cholangiocarcinoma (ICC): Preprocedural biomarkers of response
AASLD LiverLearning®, Xiao Jing Wang, 144255
Time to Initial Treatment of Hepatocellular Carcinoma in an Urban Hospital
AASLD LiverLearning®, Tae Hoon Lee, 144256
The hypoxia-mimetic agent CoCl2 induces proinflammatory and profibrotic signals as well as inflammasome activation in liver cells
AASLD LiverLearning®, Alejandra Hernández, 144512
A Short-term High Carbohydrate Diet Induces Acute Liver Injury, Enhanced de novo Lipogenesis, Inflammation, Fibrosis and M2 Macrophage Polarization
AASLD LiverLearning®, Yong Ook Kim, 144513
KBP-089, a novel Dual Amylin and Calcitonin Receptor Agonist (DACRA), reduces steatosis of the liver in a rat model of NAFLD/NASH
AASLD LiverLearning®, Sofie Gydesen, 144514
Novel LXR inverse agonists demonstrate anti-steatotic effects in human hepatocytes and in a rat model of NAFLD
AASLD LiverLearning®, Claus Kremoser, 144515
Significant of Hepatectomy for Stage B and C Hepatocellular Carcinoma in the BCLC Classification
AASLD LiverLearning®, Toshiya Kamiyama, 144270
Decellularized Liver Scaffold Promote Liver Regeneration After Partial Hepatectomy
AASLD LiverLearning®, Hirofumi Shimoda, 144271
Extemporanous HR-MAS-NMR metabolomic profiling of back-table liver grafts predicts early graft dysfunction
AASLD LiverLearning®, Francois Faitot, 144272
Treatment of Hepatitis C with ledipasvir, sofosbuvir with or without ribavirin in post liver transplant patients in an academic center.
AASLD LiverLearning®, Merlin Punnoose, 144528
Interleukin-22 exacerbates liver fibrosis in recurrent hepatitis C after liver transplantation by activating hepatic stellate cells
AASLD LiverLearning®, Hanwei LI, 144529
Impact of Acute-On-Chronic Liver Failure on 90-day Mortality following Liver Transplantation
AASLD LiverLearning®, Cyrille Feray, 144286
6 Minute Walk Test: A Quick Standardized Assessment of Functional Status and Pre-Liver Transplant Mortality
AASLD LiverLearning®, Kimberly Forde, 144287
Outcomes for patients listed for liver transplantation with a low Model for End-Stage Liver Disease (MELD) score
AASLD LiverLearning®, Arjmand Mufti, 144288
Bone Forming cells are Decreased in Osteopenic and Osteoporostic Conditions in Cirrhosis Patients.
AASLD LiverLearning®, Chhagan Bihari, 144302
Effect of long term aggressive nutritional therapy on survival in patients with alcoholic liver cirrhosis- Interim analysis of a randomized controlled trial
AASLD LiverLearning®, Chetan Kalal, 144303
Glucose homeostasis in cirrhosis: accuracy of hemoglobin a1c and potential usefulness of continuous glucose monitoring
AASLD LiverLearning®, Andres Duarte-Rojo, 144304
Oral glutamine challenge predicts and identifies long-term ammonia-related overt hepatic encephalopathy
AASLD LiverLearning®, Javier Ampuero, 144318
The VITRO Score (Von Willebrand Factor Antigen/ Thrombocyte Ratio) and its diagnostic role as a non-invasive predictor of decompensation and mortality in patients with compensated liver cirrhosis
AASLD LiverLearning®, Remy Schwarzer, 144319
Pulse Oximetry is a Poor Screening Test for Hepatopulmonary Syndrome in Liver Transplant Candidates
AASLD LiverLearning®, Kimberly Forde, 144320
The Impact of Nonselective Beta Blocker on the Liver Stiffness Measurement in Cirrhosis with Severe Portal Hypertension
AASLD LiverLearning®, Yoo Li Lim, 144334
Post-Traumatic Stress Disorder can Differentially Affect Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans
AASLD LiverLearning®, Jasmohan S. Bajaj, 144335
Is a simple screening strategy for minimal HE using Stroop Encephalapp enough to predict overt hepatic encephalopathy occurrence?
AASLD LiverLearning®, Andres Duarte-Rojo, 144336
Superior Long-Term Survival following Liver Transplantation in Patients with Alcoholic Liver Disease
AASLD LiverLearning®, George Cholankeril, 144094
Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV Genotype 1 and 4 Infected Patients
AASLD LiverLearning®, Steven Neben, 144350
Alcoholic hepatitis patients have a defect in FOXO3-dependent myeloid cell apoptosis due to high SIRT expression
AASLD LiverLearning®, Zhuan Li, 144095
Effective Prevention of Direct-acting Antiviral-resistant Hepatitis C Virus by Combination with Anti-miR-122 Therapy in Cell Culture
AASLD LiverLearning®, Tetsuro Shimakami, 144351
Myeloid Cell-Specific SIRT1 deficiency Drives Ethanol-Induced Neutrophilic Inflammation and Exacerbates Alcoholic Steatohepatitis in Mice
AASLD LiverLearning®, Min You, 144096
Hepatitis due to HBV reactivation in chronic hepatitis B and C co-infected Chinese treated with direct-acting antivirals
AASLD LiverLearning®, Weicheng Wang, 144352
Corticosteroids are the only remaining pharmacological option for severe alcoholic hepatitis: a meta-analysis of individual data on 1974 patients.
AASLD LiverLearning®, Philippe MATHURIN, 144097
Acute Kidney Injury in Alcoholic Hepatitis: Prediction by Tachycardia and Impact on Short-term survival
AASLD LiverLearning®, Sujan Ravi, 144110
Increased duodenal iron absorption through up-regulation of ferroportin 1 due to decrement of serum hepcidin in patients with chronic hepatitis C
AASLD LiverLearning®, Koji Miyanishi, 144366
Adipose-specific lipin1 overexpression protects mice against alcohol-induced liver injury
AASLD LiverLearning®, Wenliang Zhang, 144111
HCV-NS2 protease induces growth arrest in Huh7 cells, accompanied by aberrant nuclear localization of E-cadherin and increased WNT1 expression suggestive of epithelial to mesenchymal transition state
AASLD LiverLearning®, Manish Choudhary, 144367
Alcohol-induced activation of the unfolded protein response in Paneth cells induces small intestinal inflammasome activation, pro-apoptotic signaling and IL-17 production
AASLD LiverLearning®, Benedek Gyongyosi, 144112
HCV Cure: Increases Body Weight and Liver Fat Content
AASLD LiverLearning®, Isaac Wasserman, 144368
Hepatic SIRT1 is Dispensable for Adiponectin-Mediated Amelioration of Bile Acid Metabolism Abnormalities and Liver Dysfunction in Ethanol-Fed Mice
AASLD LiverLearning®, Min You, 144113
Therapeutic Potential Of Liver X Receptor (LXR) In Alcoholic Liver Disease (ALD)
AASLD LiverLearning®, Monideepa Sengupta, 144126
Alterations of the gut microbiome in the acute-on-chronic model of alcoholic hepatitis correlate with liver damage, steatosis and inflammation
AASLD LiverLearning®, Patrick Lowe, 144127
Association of T-Cell Exhaustion Markers, PD-1, TIM-3 and LAG-3 with Liver Cirrhosis, and Responses to Therapy in Chronic HCV-Infected Patients
AASLD LiverLearning®, Enass Abdel-Hameed, 144383